Healio reports.PrEP, or pre-exposure prophylaxis, uses antiretroviral treatments for HIV to prevent an HIV-negative person from contracting the virus.The most widely known form of PrEP is currently the once-per-day pill known as Truvada, manufactured by Gilead Sciences.But that daily regimen could be transformed into just 12 pills per year if Merck’s trials continue to demonstrate the efficacy of islatravir.Sharon L.
Hillier, Ph.D., professor of reproductive infectious disease at the University of Pittsburgh School of Medicine and director of reproductive infectious disease research at UPMC Magee-Women’s Hospital in Pittsburgh, told reporters that islatravir was “extremely potent [with] an extremely long half-life,” according to data from.
Read more on metroweekly.com